u/erez_yilmaz

The translation cost of dealing with a foreign pharmacy was the thing I had not budgeted for.

System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.

Small fix — those two prices are for different pack sizes, which accounts for most of the gap.

Correcting myself upthread: the criterion I quoted was updated for this year.

Careful, that guidance is from a different country and this thread is asking about somewhere else entirely.

Push back: a longer run is not automatically better resolution. You are trading peak width for time and the ratio is what matters.

Same view.

Adding the standing caveat — unapproved, and research material is not for human use.

Disagree — that name refers to at least two different molecules depending on who is selling it. The thread needs to be specific.

Bought small on anything without a testing history here. That rule has never once cost me anything.

pharmacy margins are regulated differently in each country

Is the prescription from the same country as the pharmacy?

Reimbursed or private?

Push back: strength dropping in a deficit is not the same as lean mass loss. Related, not identical.

Research-use-only labelling is a description of intended use, not a customs classification. It does not by itself determine how anything is treated at a border.

Cross-border prescription recognition exists under EU rules but is conditional and narrower than commonly assumed, with requirements about the prescription’s form and content.

Gave the same trace to two people I trust and got two integrations about a point apart. That was the most educational afternoon I have had here.

Milligram comparisons across molecule classes are meaningless. Potency is a property of the molecule at its receptor, not of the number on the label.

handling and storage vary enormously across this catalogue

Carryover from a previous high-concentration injection looks exactly like a small impurity. The blank injection is four minutes and it removes the ambiguity entirely.

I would not treat catalogue breadth as a quality signal. It is a business decision, not an analytical one.

That is an authorisation question and you have answered a reimbursement one. They are decided by different bodies.

you cannot report to two decimals off that baseline

This is the whole methodological point of the board in one line.

Research-use-only material is not approved for human use. In this catalogue that covers essentially everything, which is why the board discusses material and analytics rather than outcomes.

Small fix — 214nm, not 210. It matters for the comparison you are making with the other run.

the same product has different names and pack sizes across the union

Some lean mass loss accompanies weight loss in any deficit. Resistance training and adequate protein intake are the two interventions with the best evidence for limiting the proportion.

if it matters, ask somebody qualified in your own jurisdiction

oral and non-peptide is the whole engineering story

Yes — system suitability first. Without it the number is an assertion about the instrument, not the sample.

oral semaglutide is a peptide with an absorption enhancer, this is not that

Yes. Oral peptide with an absorption enhancer and oral small molecule are completely different propositions.

Disagree — that is the position in one country and this thread is about another. They are genuinely different.

Area percent is the integrated area of your peak over the total integrated area at one wavelength on one gradient. Change any of those and the number changes without the sample changing.

Is that from the publication or the press release?

Is that baseline drawn by the software or by hand?

Same view — reporting the gradient is what makes a result checkable rather than merely stated.

Adding one practical thing — run the blank. It answers this before anyone has to argue about it.